News

Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has signed an exclusive ...
Atelerix, a company specializing in the storage and transport of cells at room temperature, has announced that it has significantly strengthened its leadership team with two experienced industry ...
Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Va.-based biotechnology company, have signed a two-year option to license novel, small-molecule technology to ...
CAMBRIDGE, England & NEWCASTLE, England, June 03, 2024--(BUSINESS WIRE)--DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a ...
UK-based biotech innovator Atelerix has signed an exclusive distribution agreement with Chinese life science company MineBio ...
Tyneside biotech business Atelerix has struck a deal which will see it break into one of the world's biggest life science markets. Newcastle University spin-out Atelerix is revolutionising how ...
Atelerix says its system could help companies in the business of selling cells, as well as those developing and testing new drugs. CEO Mick McLean explained that the current standard method ...
View Full Profile. Learn about our Editorial Policies. Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, ...
Atelerix, announced it has signed an exclusive distribution agreement with MineBio, a leading Chinese supply chain and logistics organisation. Under the terms of the agreement, MineBio will act as the ...
Under the terms of the agreement, MineBio will act as the sole distribution partner for Atelerix’s products in China, providing solutions to traditional cryopreservation challenges by enabling ...
Hypothermic preservation technology eliminates costs and inefficiencies of cold-chain logistics to enhance biomedical research and cell therapy development NEWCASTLE, England, April 16, ...